The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
Adamis Pharma Reports Deal To Sell Portion Of US Compounding Business, No Terms Disclosed
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that it has entered into a definitive agreement to sell a significant portion of the assets of its subsidiary, US Compounding Inc. (USC), related to
Adamis Pharma Sends Letter To Shareholders, Addresses Jerald Hammann’s ‘Costly, Distracting, Misguided’ Campaign
July 1, 2021
Dear Stockholders,
The Board of Directors (the "Board") appreciates your continued investment in Adamis Pharmaceuticals Corporation ("Adamis" or the "Company" or
20 Stocks Moving in Thursday’s Pre-Market Session
Gainers
Alterity Therapeutics Ltd (NASDAQ: ATHE) shares rose 64% to $2.14 in pre-market trading. Alterity Therapeutics recently said it received EU regulatory guidance for ATH434 Phase 2 clinical trial.
Adamis Pharma Received FDA Approval on Labeling for Symjepi 0.3MG/0.3ML (0.3MG/0.3ML); 0.15MG/0.3ML (0.15MG/0.3ML)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207534
Adamis Pharma Offers Update On Clinical Trial Start-Up Progress For Tempol In Treatment Of COVID-19
Activities Proceeding for Phase 2/3 Trial Examining the Effects of Tempol for the Treatment of COVID-19
SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced